Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Microbix Biosystems Inc. (MBX.TO)
Mississauga, ON, CA
Microbix Biosystems Inc. is a life science enterprise dedicated to advancing human health globally, including markets across North America and Europe. Established in 1988 and headquartered in Mississauga, Canada, the company specializes in developing and marketing unique biological and technological products. A significant part of its business involves producing essential biological reagents for the diagnostic industry. This encompasses antigens vital for immunoassays, alongside its distinctive Quality Assessment and Proficiency (QAP) products. These QAPs are instrumental for clinical laboratories, providing support for proficiency testing, the development and validation of diagnostic assays, and optimizing routine lab operations. Furthermore, Microbix applies its deep biological knowledge and infrastructure to create additional proprietary offerings. Among these are DxTM, a viral transport medium crucial for stabilizing patient specimens prior to laboratory analysis, and Kinlytic Urokinase, a biopharmaceutical thrombolytic drug employed to treat blood clots. The company channels its QAP sales to accreditation organizations, diagnostic companies, and clinical laboratories via an extensive network of regional distributors.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.17% | -10.00% | -6.25% | -2.17% | -10.00% | -2.17% | -33.82% | -46.43% | -61.21% | -13.46% | -69.18% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-26.8% Q1'26: -36.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-162.9% Q1'26: -10,400.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-10.9% Q1'26: -15.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-7.3% Q1'26: -37.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-6.0% ★ Q1'26: -21.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.2% ★ Q1'26: -1.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×15.82× ★ Q1'26: -2.13× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Sep 2020 actual |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 1 Rev. Ana. 1 EPS Ana. |
Sep 2027 1 Rev. Ana. 1 EPS Ana. |
Sep 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
10.52M
est: 12.50M (-15.8%)
|
18.59M
est: 19.14M (-2.9%)
|
19.08M
est: 20.04M (-4.8%)
|
16.51M
est: 23.84M (-30.7%)
|
25.39M
est: 24.70M (+2.8%)
|
18.59M
est: 18.40M (+1.0%)
|
18.30M
18.30M – 18.30M
-0.5% YoY
|
20.50M
20.50M – 20.50M
+12.0% YoY
|
24.60M
24.60M – 24.60M
+20.0% YoY
|
| EBITDA |
-2.91M
est: 1.46M (-298.9%)
|
5.66M
est: 2.24M (+152.3%)
|
3.73M
est: 2.35M (+58.8%)
|
1.96M
est: 4.22M (-53.6%)
|
6.21M
est: 4.38M (+41.8%)
|
428.2K
est: 3.26M (-86.9%)
|
3.24M
3.24M – 3.24M
-0.5% YoY
|
3.63M
3.63M – 3.63M
+12.0% YoY
|
4.36M
4.36M – 4.36M
+20.0% YoY
|
| EBIT |
-3.60M
est: 720.5K (-600.1%)
|
4.84M
est: 1.10M (+338.4%)
|
2.61M
est: 1.16M (+126.0%)
|
799.9K
est: 2.66M (-69.9%)
|
4.59M
est: 2.76M (+66.6%)
|
-1.35M
est: 2.05M (-165.8%)
|
2.04M
2.04M – 2.04M
-0.5% YoY
|
2.29M
2.29M – 2.29M
+12.0% YoY
|
2.74M
2.74M – 2.74M
+20.0% YoY
|
| Net Income |
-6.23M
est: 550.0K (-1,232.4%)
|
1.63M
est: 3.85M (-57.7%)
|
1.79M
est: 2.75M (-35.0%)
|
-39.5K
est: 4.12M (-101.0%)
|
3.52M
est: 2.78M (+26.5%)
|
-2.25M
est: -2.78M (+19.3%)
|
-1.39M
-1.39M – -1.39M
+50.0% YoY
|
1.39M
1.39M – 1.39M
+200.0% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
4.17M
est: 4.62M (-9.7%)
|
5.07M
est: 7.07M (-28.2%)
|
6.56M
est: 7.41M (-11.5%)
|
8.01M
est: 9.25M (-13.4%)
|
8.88M
est: 9.59M (-7.4%)
|
9.10M
est: 7.14M (+27.4%)
|
7.10M
7.10M – 7.10M
-0.5% YoY
|
7.96M
7.96M – 7.96M
+12.0% YoY
|
9.55M
9.55M – 9.55M
+20.0% YoY
|
| EPS |
-0.06
est: 0.00 (-1,585.0%)
|
0.01
est: 0.03 (-49.3%)
|
0.01
est: 0.02 (-34.0%)
|
0.00
est: 0.03 (-101.0%)
|
0.03
est: 0.02 (+29.0%)
|
-0.02
est: -0.02 (+19.5%)
|
-0.01
-0.01 – -0.01
+50.0% YoY
|
0.01
0.01 – 0.01
+200.0% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cameron L. Groome | President, Chief Executive Officer & Director | 481.7K | male |
| Kenneth Hughes | Chief Operating Officer | 312.1K | — |
| James S. Currie | Chief Financial Officer | 310.9K | male |
| Phillip Casselli | Senior Vice President of Sales & Business Development | 300.2K | male |
| Mark Luscher | Senior Vice President of Scientific Affairs | 283.7K | — |
| Christopher Lobb | Compliance Officer, General Counsel & Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MBX.TO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
